72 Results for "

4T1 tumor

" in MedChemExpress (MCE) Product Catalog:
Products (72)

72 Results for "4T1 tumor" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-N0841
CAS No.: 25514-31-2
Synonyms: Dihydrobrusatol; NSC310616
Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (Kd: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144088
CAS No.: 2380300-79-6
Purity:  98.86%
Synonyms: HPK1-IN-22
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology Cancer

ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147165
CAS No.: 2999763-09-4
Purity:  99.58%
Research Areas:  

Cancer

VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids . VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990682

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Rat IgG2b kappa, Isotype Control is a rat IgG2b κ antibody isotype control. Rat IgG2b kappa, Isotype Control can be used as a negative control to exclude or reduce false positive results caused by nonspecific binding .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W591424
CAS No.: 92451-01-9
Synonyms: mPEG2000-SC; mPEG2000-Succinimidyl ester
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions .
loading...
    loading...
Cat. No.: HY-140736
CAS No.: 385437-57-0
Purity:  ≥95.0%
Research Areas:  

Cancer

DSPE-PEG2000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG2000) and a biotin tag. DSPE-PEG2000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
loading...
    loading...
Cat. No.: HY-101466
CAS No.: 1622204-21-0
Purity:  99.64%
Target:  

FGFR

Research Areas:  

Cancer

E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively .
loading...
    loading...
Cat. No.: HY-162312
CAS No.: 2758090-62-7
Research Areas:  

Cancer

LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model .
loading...
    loading...
Cat. No.: HY-W134005
CAS No.: 29932-54-5
Synonyms: Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate
Mg(Ⅱ)-EDTA (Ethylenediaminetetraacetic acid magnesium) disodium tetrahydrate is a divalent metal chelator and ferroptosis inducer. Mg (Ⅱ)-EDTA disodium tetrahydrate reduces E-cadherin expression by chelating Ca 2+ on the surface of tumor cells, thereby triggering cell dissociation and inducing epithelial-mesenchymal transition (EMT). Mg (Ⅱ)-EDTA disodium tetrahydrate further chelates lysosomal iron to form EDTA-Fe, induces ferroptosis through the Fenton reaction, and synergistically enhances immune responses to inhibit tumor metastasis. Mg (Ⅱ)-EDTA (disodium tetrahydrate) can be used in tumor-related research .
loading...
    loading...
Cat. No.: HY-P10449
CAS No.: 3098205-40-1
Target:  

Peptides

Research Areas:  

Inflammation/Immunology Cancer

M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-158045
CAS No.: 3032324-56-1
Purity:  99.86%
Target:  

PROTACs PARP

Research Areas:  

Cancer

PROTAC PARP1 degrader-1 is a PARP1 PROTAC degrader with a DC50 value of 252.5 nM. PROTAC PARP1 degrader-1, combined with Daunorubicin (HY-13062A), induces the accumulation of cytoplasmic DNA fragments, activates the cGAS/STING innate immune pathway, and remodels the tumor microenvironment. PROTAC PARP1 degrader-1 can be used in research related to breast cancer .
loading...
    loading...
Cat. No.: HY-156096
CAS No.: 3033039-28-7
HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
loading...
    loading...
Cat. No.: HY-175714
CAS No.: 3033532-05-4
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies .
loading...
    loading...
Cat. No.: HY-146231
CAS No.: 2636072-62-1
Target:  

PROTACs MAP4K

Research Areas:  

Inflammation/Immunology Cancer

SS47 is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 can be used in breast cancer-related research .
loading...
    loading...
Cat. No.: HY-155052
CAS No.: 2642327-52-2
Research Areas:  

Cancer

PAD4-IN-2 is a highly tumor-targeted and irreversible PAD4 inhibitor with an IC50 of 1.94 μM. It selectively recognizes sialic acid on tumor surfaces and accumulates in tumor tissues, with distribution in the cytoplasm of tumor cells and nuclei of neutrophils. PAD4-IN-2 inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization. The compound exhibits potent anti-tumor and anti-metastatic activities and is suitable for breast cancer research .
loading...
    loading...
Cat. No.: HY-P990299

Target:  

Phosphatase

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor .
loading...
    loading...
Cat. No.: HY-174811
PROTAC BRD4 Degrader-33 is an enzyme activated clickable BRD4 PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model .
loading...
    loading...
Cat. No.: HY-140736A
CAS No.: 385437-57-0
Research Areas:  

Cancer

DSPE-PEG1000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG1000) and a biotin tag. DSPE-PEG1000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
loading...
    loading...
Cat. No.: HY-140736B
CAS No.: 385437-57-0
Research Areas:  

Cancer

DSPE-PEG5000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG5000) and a biotin tag. DSPE-PEG5000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
loading...
    loading...
Cat. No.: HY-155052A
Purity:  95.64%
Research Areas:  

Cancer

PAD4-IN-2 TFA is a highly tumor-targeted and irreversible PAD4 inhibitor with an IC50 of 1.94 μM. PAD4-IN-2 TFA selectively recognizes sialic acid on tumor surfaces and accumulates in tumor tissues, with distribution in the cytoplasm of tumor cells and nuclei of neutrophils. PAD4-IN-2 TFA inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization. The compound exhibits potent anti-tumor and anti-metastatic activities and is suitable for breast cancer research .
loading...
    loading...